MedTrace Logo

Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)

NCT02221830 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-05-07

No results posted yet for this study

Summary

Evaluation of the efficacy of postpartum 24 hour oxytocin infusion to reduce blood loss in patients with pre-eclampsia (PE)

Conditions

Interventions

DRUG

Oxytocin

Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)

DRUG

Placebo

This intervention utilizes a Placebo Camparator

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Amy Hermesch, MD · University of Colorado, Denver

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2019-07-17
Completion
2019-07-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02221830 on ClinicalTrials.gov